17:22 , Jul 20, 2018 |  BC Week In Review  |  Company News

U of Helsinki grants Herantis rights to a non-invasive CDNF approach

University of Helsinki (Helsinki, Finland) granted Herantis Pharma plc (HSE:HRTIS) exclusive, worldwide rights to a therapeutic approach for non-invasive delivery of cerebral dopamine neurotrophic factor (CDNF) based on a modification of natural CDNF. The partners...